

Correction

Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study

In this article (Clin Cancer Res 2009;15:5584–90), which published in the September 1, 2009, issue of *Clinical Cancer Research* (1), in the Results section, General subsection, the third sentence should read, as follows: In addition, 15 patients received 124 cycles of mapatumumab monotherapy (median, 6; range, 2-48). Also, in the Results section, Pharmacokinetics subsection, first sentence of the last paragraph should read, as follows: Mean (with 95% confidence interval) exposure in cycles 1 and 2, as measured by Area Under the Curve C_0 , $AUC_{0-\infty}$, or AUC_{last} for gemcitabine, 2-difluoro-2-deoxyuridine, and cisplatin-derived unbound platinum is summarized by cohort in Supplementary Table S2.

Reference

1. Mom CH, Verweij J, Oldenhuis CNAM, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009;15:5584–90.

Published OnlineFirst 10/27/09.
© 2009 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-15-21-COR1

Clinical Cancer Research

Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study

Clin Cancer Res 2009;15:6744. Published OnlineFirst November 2, 2009.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-15-21-COR1](https://doi.org/10.1158/1078-0432.CCR-15-21-COR1)

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/15/21/6744.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/15/21/6744>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.